The COVID-19 vaccine made by Johnson & Johnson is 66 per cent effective in preventing moderate to severe disease — although it was found to be 72 per cent effective in U.S. clinical trials. Canada has ordered 10 million doses — with options for an additional 28 million. #cdnpoli
The vaccine appears to be much less effective against the South African variant — J&J has reported a 57 per cent efficacy rate — which is troubling because that strain has spread to other countries, including the U.S.
The vaccine candidate was 85 per cent effective in preventing severe disease across all regions studied, 28 days after vaccination in all adults 18 years and older.
The J&J product also demonstrated complete protection against COVID-related hospitalization and death, 28 days post-vaccination.
The company says the single-shot vaccine has "the potential to significantly reduce the burden of severe disease."
The company says the single-shot vaccine has "the potential to significantly reduce the burden of severe disease."
"85 per cent efficacy in preventing severe COVID-19 disease and prevention of COVID-19-related medical interventions will potentially protect hundreds of millions of people from serious and fatal outcomes," J&J says. (Health Canada regulators are still reviewing this product.)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
